INDEX
ABOUT JUNSHI
THERAPEUTIC AREAS
PRESS RELEASES
CAREERS
INVESTORS
CONTACT
Entrance
中文简体
中文繁体
EN
Menu
INDEX
ABOUT JUNSHI
THERAPEUTIC AREAS
PRESS RELEASES
CAREERS
INVESTORS
CONTACT
中文简体
中文繁体
EN
PRESS RELEASES
NMPA Accepted sNDA for Toripalimab Plus Chemo as 1st-Line Treatment for ESCC
07-29
2021
Junshi Biosciences and Immorna to Develop Innovative mRNA Therapeutics and Vaccines
07-19
2021
JUPITER-02 Data Presented at 2021 ASCO Pleneray Session
06-03
2021
Toripalimab as 1st-Line Treatment for ESCC Reached Primary Endpoints in Phase III Clinical Study
04-22
2021
More
Back
List
//
